Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis

NCT04033926 is registered in ClinicalTrials.gov with Kezar Life Sciences, Inc. as lead sponsor.

NCT NCT04033926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04033926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis
Lead sponsor
Kezar Life Sciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 14, 2020
Completion date
April 6, 2022
Enrollment
25 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, polymyositis